18 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Oct 2038. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Oct 2038
Next term end
9
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Aug 2040 · High confidence
Also notable
Ends Sep 2039 · High confidence
Also notable
Ends May 2040 · High confidence
Gene Therapies for Lysosomal Disorders
US 11,802,294
Cited by 7 later US patents, top 10% of utility patents granted in 2023 in our data. Protection runs to 2040.
Gene Therapies for Lysosomal Disorders
US 11,661,585
Cited by 5 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2039.
Gene Therapies for Lysosomal Disorders
US 11,807,849
Cited by 6 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2040.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 30, 2026The maintenance fee for Gene Therapies for Lysosomal Disorders (US 11,661,585) comes due Nov 30, 2026. Unpaid by Jun 1, 2027, it lapses early.
- 1 fee due Apr 30, 2027The maintenance fee for Gene Therapies for Lysosomal Disorders (US 11,802,294) comes due Apr 30, 2027. Unpaid by Nov 1, 2027, it lapses early.
- 1 fee due May 7, 2027The maintenance fee for Gene Therapies for Lysosomal Disorders (US 11,807,849) comes due May 7, 2027. Unpaid by Nov 8, 2027, it lapses early.
- 1 fee due Aug 20, 2027The maintenance fee for Gene Therapies for Lysosomal Disorders (US 11,903,985) comes due Aug 20, 2027. Unpaid by Feb 22, 2028, it lapses early.
Recent changes
- 4 of the patents on this record were granted since Aug 19, 2026
What they patent
The 5 largest of its 9 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Gene Therapies for Lysosomal Disorders (2019) | 5 in force | to Aug 2041 |
| Gene Therapies for Lysosomal Disorders (2019) | 4 in force | to Aug 2040 |
| Gene Therapies for Lysosomal Disorders (2020) | 2 in force | to Apr 2042 |
| Gene Therapies for Lysosomal Disorders (2020) | 2 in force | to Jul 2040 |
| Assay for Measuring Potency of Gene Therapy Drug Product | 1 in force | to Feb 2044 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,689,625 | Gene Therapies for Lysosomal Disorders In force · Medium confidence | In force | Medium confidence | |
| US 10,837,028 | Gene Therapies for Lysosomal Disorders In force · High confidence | In force | High confidence | |
| US 11,060,113 | Gene Therapies for Lysosomal Disorders In force · High confidence | In force | High confidence | |
| US 11,903,985 | Gene Therapies for Lysosomal Disorders In force · High confidence | In force | High confidence | |
| US 12,516,298 | Gene Therapies for Lysosomal Disorders In force · High confidence | In force | High confidence | |
| US 12,571,002 | Gene Therapies for Lysosomal Disorders In force · High confidence | In force | High confidence | |
| US 11,661,585 | Gene Therapies for Lysosomal Disorders In force · High confidence | In force | High confidence | |
| US 11,655,460 | Gene Therapies for Lysosomal Disorders In force · Medium confidence | In force | Medium confidence | |
| US 12,570,963 | Gene Therapies for Lysosomal Disorders In force · Medium confidence | In force | Medium confidence | |
| US 11,807,849 | Gene Therapies for Lysosomal Disorders In force · High confidence | In force | High confidence |
Also on record, not counted in the 18: 8 applications pending · 7 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.